Building the World’s First Comprehensive Pro-resolution Platform for Drug Discovery in Inflammatory Diseases
A Better Therapeutic Option
Resolve M aims to harness innate immune pro-resolving responses to address inflammatory disorders without completely shutting down the immune system, providing a better therapeutic option in the chronic setting.
About Us
Resolve M was created through a strategic collaboration between Johnson & Johnson’s venture arm, JJDC, and General Inception, the global biotech company igniter, and reflects a bold commitment to early-stage biotech innovation.
